{"parse":{"title":"Eroom's law","pageid":48037281,"revid":836565606,"text":{"*":"<div class=\"mw-parser-output\"><p><b>Eroom's law</b> is the observation that drug discovery is becoming slower and more expensive over time, despite improvements in technology (such as <a href=\"/wiki/High_throughput_screening\" class=\"mw-redirect\" title=\"High throughput screening\">high throughput screening</a>, <a href=\"/wiki/Biotechnology\" title=\"Biotechnology\">biotechnology</a>, <a href=\"/wiki/Combinatorial_chemistry\" title=\"Combinatorial chemistry\">combinatorial chemistry</a>, and computational <a href=\"/wiki/Drug_design\" title=\"Drug design\">drug design</a>), a trend first observed in the 1980s. The cost of developing a new drug roughly doubles every nine years (inflation-adjusted).<sup id=\"cite_ref-MyUser_Pipeline.corante.com_October_3_2015c_1-0\" class=\"reference\"><a href=\"#cite_note-MyUser_Pipeline.corante.com_October_3_2015c-1\">&#91;1&#93;</a></sup> In order to highlight the contrast with the exponential advancements of other forms of technology (such as <a href=\"/wiki/Transistors\" class=\"mw-redirect\" title=\"Transistors\">transistors</a>) over time, the law was deliberately spelled as <a href=\"/wiki/Moore%27s_law\" title=\"Moore&#39;s law\">Moore's law</a> spelled backwards.\n</p><p>The law is attributed to four main causes.<sup id=\"cite_ref-MyUser_Nature.com_October_16_2015c_2-0\" class=\"reference\"><a href=\"#cite_note-MyUser_Nature.com_October_16_2015c-2\">&#91;2&#93;</a></sup>\n</p>\n<ul><li><b>the 'better than the Beatles' problem</b>: the sense that new drugs only have modest incremental benefit over drugs already widely considered as successful, such as <a href=\"/wiki/Lipitor\" class=\"mw-redirect\" title=\"Lipitor\">Lipitor</a>, and treatment effects on top of already effective treatments are smaller than treatment effects versus placebo. The smaller size of these treatment effects mandates an increase in clinical trial sizes to show the same level of efficacy. This problem was phrased as \"better than the Beatles\" to highlight the fact that it would be difficult to come up with new successful pop songs if all new songs had to be better than <a href=\"/wiki/The_Beatles\" title=\"The Beatles\">the Beatles</a>.</li>\n<li><b>the 'cautious regulator' problem</b>: the progressive lowering of risk tolerance seen by drug regulatory agencies that makes <a href=\"/wiki/R%26D\" class=\"mw-redirect\" title=\"R&amp;D\">R&amp;D</a> both costlier and harder. After older drugs (such as <a href=\"/wiki/Thalidomide\" title=\"Thalidomide\">Thalidomide</a> or <a href=\"/wiki/Vioxx\" class=\"mw-redirect\" title=\"Vioxx\">Vioxx</a>) are removed from the market due to safety reasons, the bar on safety for new drugs is increased.</li>\n<li><b>the 'throw money at it' tendency</b>: the tendency to add human resources and other resources to R&amp;D, which may lead to project overrun.</li>\n<li><b>the 'basic research\u2013brute force' bias</b>: the tendency to overestimate the ability of advances in basic research and brute force screening methods to show a molecule as safe and effective in clinical trials. From the 1960s to the 1990s (and later), drug discovery has shifted from whole-animal <a href=\"/wiki/Classical_pharmacology\" title=\"Classical pharmacology\">classical pharmacology</a> testing methods (<a href=\"/wiki/Phenotypic_screening\" title=\"Phenotypic screening\">phenotypic screening</a>) to <a href=\"/wiki/Reverse_pharmacology\" title=\"Reverse pharmacology\">reverse pharmacology</a> target-approaches that result in the discovery of drugs that may tightly bind with high-affinity to target proteins, but which still often fail in clinical trials due to an under-appreciation of the complexity of the whole organism.<sup id=\"cite_ref-MyUser_Wavefunction.fieldofscience.com_October_16_2015c_3-0\" class=\"reference\"><a href=\"#cite_note-MyUser_Wavefunction.fieldofscience.com_October_16_2015c-3\">&#91;3&#93;</a></sup> Furthermore, drug discovery techniques have shifted from small-molecule and iterative low-throughput search strategies to target-based <a href=\"/wiki/High-throughput_screening\" title=\"High-throughput screening\">high-throughput screening</a> (HTS) of large compound libraries. But despite being faster and cheaper, HTS approaches may be less productive.</li></ul>\n<p>While some suspect a lack of \"low hanging fruit\" as a significant contribution to Eroom's law, this may be less important than the four main causes, as there are still many decades worth of new potential drug targets relative to the number of targets which already have been exploited, even if the industry exploits 4-5 new targets per year.<sup id=\"cite_ref-MyUser_Nature.com_October_16_2015c_2-1\" class=\"reference\"><a href=\"#cite_note-MyUser_Nature.com_October_16_2015c-2\">&#91;2&#93;</a></sup> There is also space to explore selectively non-selective drugs (or \"<a href=\"/wiki/Dirty_drug\" title=\"Dirty drug\">dirty drugs</a>\") that interact with several molecular targets, and which may be particularly effective as central nervous system (CNS) therapeutics, even though few of them have been introduced in the last few decades.<sup id=\"cite_ref-nature2_4-0\" class=\"reference\"><a href=\"#cite_note-nature2-4\">&#91;4&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"References\">References</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Eroom%27s_law&amp;action=edit&amp;section=1\" title=\"Edit section: References\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<div class=\"reflist\" style=\"list-style-type: decimal;\">\n<div class=\"mw-references-wrap\"><ol class=\"references\">\n<li id=\"cite_note-MyUser_Pipeline.corante.com_October_3_2015c-1\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-MyUser_Pipeline.corante.com_October_3_2015c_1-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">Lowe D (8 March 2012). <a rel=\"nofollow\" class=\"external text\" href=\"http://blogs.sciencemag.org/pipeline/archives/2012/03/08/erooms_law\">\"Eroom's Law\"</a>. <i>In the Pipeline</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">16 October</span> 2015</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=In+the+Pipeline&amp;rft.atitle=Eroom%E2%80%99s+Law&amp;rft.date=2012-03-08&amp;rft.aulast=Lowe&amp;rft.aufirst=D&amp;rft_id=http%3A%2F%2Fblogs.sciencemag.org%2Fpipeline%2Farchives%2F2012%2F03%2F08%2Ferooms_law&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AEroom%27s+law\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-MyUser_Nature.com_October_16_2015c-2\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-MyUser_Nature.com_October_16_2015c_2-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-MyUser_Nature.com_October_16_2015c_2-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Scannell JW, Blanckley A, Boldon H, Warrington B (2012). \"Diagnosing the decline in pharmaceutical R&amp;D efficiency\". <i>Nature Reviews. Drug Discovery</i>. <b>11</b> (3): 191\u2013200. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1038/nrd3681\">10.1038/nrd3681</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/22378269\">22378269</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Nature+Reviews.+Drug+Discovery&amp;rft.atitle=Diagnosing+the+decline+in+pharmaceutical+R%26D+efficiency&amp;rft.volume=11&amp;rft.issue=3&amp;rft.pages=191-200&amp;rft.date=2012&amp;rft_id=info%3Adoi%2F10.1038%2Fnrd3681&amp;rft_id=info%3Apmid%2F22378269&amp;rft.aulast=Scannell&amp;rft.aufirst=JW&amp;rft.au=Blanckley%2C+A&amp;rft.au=Boldon%2C+H&amp;rft.au=Warrington%2C+B&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AEroom%27s+law\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-MyUser_Wavefunction.fieldofscience.com_October_16_2015c-3\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-MyUser_Wavefunction.fieldofscience.com_October_16_2015c_3-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">Jogalekar A (8 March 2012). <a rel=\"nofollow\" class=\"external text\" href=\"http://wavefunction.fieldofscience.com/2012/03/unstoppable-moore-hits-immovable-eroom.html\">\"The unstoppable Moore hits the immovable Eroom\"</a>. <i>The Curious Wavefunction</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">16 October</span> 2015</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=The+Curious+Wavefunction&amp;rft.atitle=The+unstoppable+Moore+hits+the+immovable+Eroom&amp;rft.date=2012-03-08&amp;rft.aulast=Jogalekar&amp;rft.aufirst=A&amp;rft_id=http%3A%2F%2Fwavefunction.fieldofscience.com%2F2012%2F03%2Funstoppable-moore-hits-immovable-eroom.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AEroom%27s+law\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-nature2-4\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-nature2_4-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Roth BL, Sheffler DJ, Kroeze WK (2004). \"Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia\". <i>Nature Reviews. Drug Discovery</i>. <b>3</b> (4): 353\u20139. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1038/nrd1346\">10.1038/nrd1346</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/15060530\">15060530</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Nature+Reviews.+Drug+Discovery&amp;rft.atitle=Magic+shotguns+versus+magic+bullets%3A+selectively+non-selective+drugs+for+mood+disorders+and+schizophrenia&amp;rft.volume=3&amp;rft.issue=4&amp;rft.pages=353-9&amp;rft.date=2004&amp;rft_id=info%3Adoi%2F10.1038%2Fnrd1346&amp;rft_id=info%3Apmid%2F15060530&amp;rft.aulast=Roth&amp;rft.aufirst=BL&amp;rft.au=Sheffler%2C+DJ&amp;rft.au=Kroeze%2C+WK&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AEroom%27s+law\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n</ol></div></div>\n\n<!-- \nNewPP limit report\nParsed by mw1331\nCached time: 20180908065436\nCache expiry: 1900800\nDynamic content: false\nCPU time usage: 0.076 seconds\nReal time usage: 0.093 seconds\nPreprocessor visited node count: 231/1000000\nPreprocessor generated node count: 0/1500000\nPost\u2010expand include size: 7127/2097152 bytes\nTemplate argument size: 79/2097152 bytes\nHighest expansion depth: 7/40\nExpensive parser function count: 0/500\nUnstrip recursion depth: 0/20\nUnstrip post\u2010expand size: 5651/5000000 bytes\nNumber of Wikibase entities loaded: 0/400\nLua time usage: 0.035/10.000 seconds\nLua memory usage: 2.09 MB/50 MB\n-->\n<!--\nTransclusion expansion time report (%,ms,calls,template)\n100.00%   75.982      1 Template:Reflist\n100.00%   75.982      1 -total\n 66.94%   50.859      2 Template:Cite_web\n 14.49%   11.012      2 Template:Cite_journal\n  2.79%    2.120      1 Template:Main_other\n-->\n\n<!-- Saved in parser cache with key enwiki:pcache:idhash:48037281-0!canonical and timestamp 20180908065436 and revision id 836565606\n -->\n</div>"},"langlinks":[],"categories":[{"sortkey":"","*":"Drug_discovery"},{"sortkey":"","*":"Rules_of_thumb"}],"links":[{"ns":0,"exists":"","*":"Biotechnology"},{"ns":0,"exists":"","*":"Classical pharmacology"},{"ns":0,"exists":"","*":"Combinatorial chemistry"},{"ns":0,"exists":"","*":"Digital object identifier"},{"ns":0,"exists":"","*":"Dirty drug"},{"ns":0,"exists":"","*":"Drug design"},{"ns":0,"exists":"","*":"High-throughput screening"},{"ns":0,"exists":"","*":"High throughput screening"},{"ns":0,"exists":"","*":"Lipitor"},{"ns":0,"exists":"","*":"Moore's law"},{"ns":0,"exists":"","*":"Phenotypic screening"},{"ns":0,"exists":"","*":"PubMed Identifier"},{"ns":0,"exists":"","*":"R&D"},{"ns":0,"exists":"","*":"Reverse pharmacology"},{"ns":0,"exists":"","*":"Thalidomide"},{"ns":0,"exists":"","*":"The Beatles"},{"ns":0,"exists":"","*":"Transistors"},{"ns":0,"exists":"","*":"Vioxx"}],"templates":[{"ns":10,"exists":"","*":"Template:Reflist"},{"ns":10,"exists":"","*":"Template:Cite web"},{"ns":10,"exists":"","*":"Template:Cite journal"},{"ns":10,"exists":"","*":"Template:Main other"},{"ns":828,"exists":"","*":"Module:Citation/CS1"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Configuration"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Whitelist"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Utilities"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Date validation"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Identifiers"},{"ns":828,"exists":"","*":"Module:Citation/CS1/COinS"},{"ns":828,"exists":"","*":"Module:Check for unknown parameters"}],"images":[],"externallinks":["http://blogs.sciencemag.org/pipeline/archives/2012/03/08/erooms_law","//doi.org/10.1038/nrd3681","//www.ncbi.nlm.nih.gov/pubmed/22378269","http://wavefunction.fieldofscience.com/2012/03/unstoppable-moore-hits-immovable-eroom.html","//doi.org/10.1038/nrd1346","//www.ncbi.nlm.nih.gov/pubmed/15060530"],"sections":[{"toclevel":1,"level":"2","line":"References","number":"1","index":"1","fromtitle":"Eroom's_law","byteoffset":4629,"anchor":"References"}],"parsewarnings":[],"displaytitle":"Eroom's law","iwlinks":[],"properties":[{"name":"wikibase_item","*":"Q25326591"}]}}